Modeling the estrogen receptor to growth factor receptor signaling switch in human breast cancer cells  by Chen, Chun et al.
FEBS Letters 587 (2013) 3327–3334journal homepage: www.FEBSLetters .orgModeling the estrogen receptor to growth factor receptor signaling
switch in human breast cancer cells0014-5793/$36.00  2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
http://dx.doi.org/10.1016/j.febslet.2013.08.022
Abbreviations: AKT, a serine/threonine-speciﬁc protein kinase, also known as
Protein Kinase B (PKB); CCS, charcoal-stripped fetal-calf serum; CSC, cancer stem
cell; E2, 17b-estradiol; E2:ER, E2-bound estrogen receptor; EGFR, epidermal growth
factor receptor; ER, estrogen receptor; ER-P, phosphorylated estrogen receptor; FCS,
fetal calf serum; GFR, growth factor receptor; HER2, human epidermal growth
factor receptor-2; MAPK, mitogen activated protein kinases; mTOR, mammalian
target of rapamycin; NFjB, nuclear factor kappa-light-chain-enhancer of activated
B cells; PI3K, phosphatidylinositide 3-kinases
⇑ Corresponding author. Fax: +1 540 231 9307.
E-mail address: tyson@vt.edu (J.J. Tyson).Chun Chen c, William T. Baumann b, Robert Clarke d, John J. Tyson a,⇑
aDepartment of Biological Sciences, Virginia Polytechnic Institute & State University, Blacksburg, VA 24061, USA
bDepartment of Electrical & Computer Engineering, Virginia Polytechnic Institute & State University, Blacksburg, VA 24061, USA
cGraduate Program in Genetics, Bioinformatics and Computational Biology, Virginia Polytechnic Institute & State University, Blacksburg, VA 24061, USA
d Lombardi Comprehensive Cancer Center, Georgetown University School of Medicine, Washington, DC 20057, USA
a r t i c l e i n f o a b s t r a c tArticle history:
Received 19 June 2013
Revised 6 August 2013
Accepted 12 August 2013
Available online 28 August 2013
Edited by Paul Bertone
Keywords:
Mathematical modeling
Estrogen receptor signaling
Growth factor receptor signaling
Breast cancer
Endocrine resistanceBreast cancer cells develop resistance to endocrine therapies by shifting between estrogen receptor
(ER)-regulated and growth factor receptor (GFR)-regulated survival signaling pathways. To study
this switch, we propose a mathematical model of crosstalk between these pathways. The model
explains why MCF7 sub-clones transfected with HER2 or EGFR show three GFR-distribution patterns,
and why the bimodal distribution pattern can be reversibly modulated by estrogen. The model illus-
trates how transient overexpression of ER activates GFR signaling and promotes estrogen-indepen-
dent growth. Understanding this survival-signaling switch can help in the design of future therapies
to overcome resistance in breast cancer.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Mammalian cells can switch between different signaling
pathways to achieve distinct physiological goals in response to
environmental stimuli, as exempliﬁed by immune cell differentia-
tion [1]. This plasticity is important for normal cells to differentiate
properly and to survive in stressful environments. In cancer cells,
this plasticity often results in drug resistance including acquired
resistance to anti-estrogenic drugs.
The estrogen receptor (ER) and growth factor receptor (GFR)
pathways are major drivers of survival and proliferation in 85%
of breast tumors [2,3]. In clinical practice, expression of ERa (the
most prevalent of two ER genes) and HER2 (a major GFR and mem-
ber of the EGFR superfamily) are validated biomarkers used todetermine treatment strategies for individual patients [4]. Approx-
imately 70% of breast cancers express ERa [5], and various
endocrine therapies have been developed to interfere with ER
action [5]. Antagonizing GFR pathways (e.g., using trastuzumab)
in HER2+ breast cancer also improves disease-free and overall sur-
vival for breast cancer patients [6]. However, the ultimate efﬁcacy
of therapies targeting individual pathways is not satisfactory. For
example, tamoxifen successfully reduces by one-third the annual
death rate from breast cancer, but one-third of tamoxifen-treated
women develop recurrent disease within 15 years [5]. Resistance
to anti-estrogens or GFR pathway antagonists also develops in hu-
man breast cancer cell lines [7–9].
We have used mathematical modeling guided by experimental
observations to explore the mechanism underlying acquired resis-
tance to endocrine therapies as driven by the ER–GFR switch. Ac-
quired resistance could arise by activation of a compensatory
escape pathway when the normal driver pathway is inhibited [3],
the so-called ‘hybrid-car’ model of breast cancer [10]. Since breast
cancer cells can switch reversibly and robustly between ER and
GFR pathways for proliferation and survival [3,10], blocking either
the ER or GFR pathway will usually result in activation of the other,
allowing some cells to survive and eventually resume proliferation.
Evidence for a close regulatory relationship between ER and GFR
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breast cancers [11], and activation of GFR pathway components
(HER2, EGFR, MAPK, PI3K, AKT, mTOR, NFjB etc.) as compensatory
responses to anti-estrogens [5,12–14]. Interestingly, these com-
pensatory processes are reversible after withdrawing the endo-
crine treatment [15]. Moreover, recent evidence indicates that ER
negative (ER) breast cancer cells may develop resistance to GFR
pathway antagonists by restoring the ER pathway and hence
becoming responsive to anti-estrogens [16,17].
ER and GFR are sometimes positively associated in breast can-
cers [18,19]. Whether ER and GFR are negatively or positively cor-
related depends on how ER is activated. ER can be activated either
by binding to 17b-estradiol (E2, the primary estrogen present in
breast tumors) to form an active E2:ER complex, or by phosphory-
lation (ER-P) by various kinases (e.g., ERK and AKT) at multiple
sites [5,20,21]. E2:ER has an inhibitory effect on GFR. E2 with-
drawal can release the inhibition of ER on GFR expression and
NFjB activity [22–26], consistent with the fact that E2:ER binds
the promoter region of GFR genes (e.g., HER2 and EGFR) and acts
as a repressor [27,28]. However, E2-independent ER-P is positively
associated with GFR, and it can up-regulate certain ligands (e.g.,
TGFa, EGF and amphiregulin) of the GFR signaling network, which
in turn activate the kinases that phosphorylate more ER [29–31].
This auto-activation loop has been implicated in tamoxifen-
resistance [31,32]. NFjB, a major integrator of the GFR signaling
network, is involved with E2:ER in a mutual-inhibition feedback
loop [24,33]. NFjB also controls the expression of a broad spec-
trum of genes regulating important cellular behaviors including
cell differentiation [34,35]. In particular, NFjB activates the
transcription factor TWIST and represses the expression of
E-cadherin, which in turn enhances the epithelial–mesenchymal
transition (EMT) in breast cancer [36]. EMT is associated with a
de-differentiation process whereby epithelial-like breast cancer
cells increase their ‘stemness’ and undergo a phenotypic transition
from HER2 to HER2+ [37]. EMT in breast cancer cells is likely due
to genome-scale epigenetic reprogramming, including the pro-
moter activity of HER2 [38]. Epigenetic changes such as
methylation or acetylation can occur during differentiation or
de-differentiation and are often reversible [36–38].
While the crosstalk between ER and GFR pathways in breast
cancer, especially in MCF7 cells, has been widely studied
[5,13,20,22,31,39,40], a comprehensive, dynamic view of ER–GFR
crosstalk is still lacking. Previously, we proposed a simpliﬁed
model that could account for the effects of E2 withdrawal on the
bimodal distribution of GFR (HER2 or EGFR) in MCF7 cells [41].
However, this model combined all components of the GFR pathway
into one variable and required an unreasonably slow rate constant
to ﬁt the experimental data. A more realistic model would allow
the GFR pathway to exhibit both rapid (e.g., post-translational
modiﬁcations of GFR proteins) and slow modiﬁcations (e.g., epige-
netic modiﬁcations of GFR promoters). Moreover, a recent report
indicates that transient ER overexpression can robustly activate
E2-independent growth of MCF7 cells [42], suggesting further
modiﬁcations to achieve a more realistic model.
Here we present a new model to explore the mathematical
characteristics of the ER–GFR switch that is a central determinant
of breast cancer cell fate in response to endocrine therapies. The
model explains many aspects of the available experimental data
(Supplementary document, Fig. S1–S4), for example: (1) in
sub-clones of MCF7 cells transfected with GFR (HER2 or EGFR),
there are three different distribution patterns of GFR [43,44]
(Fig. S1), (2) for sub-clones with a bimodal distribution of GFR,
the distribution can be reversibly manipulated by varying E2 levels
[43,44] (Fig. S2), (3) whereas E2 withdrawal in GFR-transfected
MCF7 cells switches on GFR expression within weeks, E2 addition
takes months to switch off expression [43,44] (Fig. S2), (4) E2withdrawal can up-regulate GFR expression within 5 weeks in
GFR-transfected MCF7 cells, but fails to do so in wild type MCF7
cells [43,44] (Fig. S3), and (5) transient ER overexpression in
MCF7 cells can switch on the GFR pathway and promote E2-inde-
pendent growth [42] (Fig. S4). The model provides a new tool to
understand and evaluate these intriguing experimental observa-
tions, and it may help in ﬁnding new strategies to overcome
anti-estrogen resistance in breast cancer.2. Materials and methods
We postulate a highly condensed model of the interaction be-
tween ER and GFR (Fig. 1A and Supplementary documents). The
protein level of GFR is down-regulated by E2:ER complex [27,28].
After E2 withdrawal, GFR is released from inhibition and its down-
stream kinases phosphorylate ER to an E2-independent form, ER-P
[5,20,21]. ER-P can activate and stabilize the GFR pathway, creating
a positive feedback loop [29–31]. In addition, GFR further activates
transcription factors such as NFjB, promoting a series of epigenetic
changes contributing to increased GFR expression and establishing
another positive feedback loop [34,35]. For simplicity, we combine
the epigenetic factors contributing to GFR expression into the
quantity ‘EPI’. ‘E2ER’ and ‘ERP’ are used to represent [E2:ER] and
[ER-P]. The wiring diagram in Fig. 1A was translated into ordinary
differential equations (ODEs) by a formalism that allows us to cap-
ture complex dependencies in a simple manner [45] for simulation
and analysis. We used the program XPP-AUT, available freely at
http://www.math.pitt.edu/~bard/xpp/xpp.html, to simulate the
model and to draw bifurcation diagrams. The ensemble stochastic
simulations were performed with Matlab Version 7.9.0. A detailed
version of materials andmethods is provided in the Supplementary
document.
3. Results
3.1. Bifurcation analysis of the survival-signaling switch
The nullclines of our system of equations (Eq. S1 and S2) are
plotted in Fig. 1B. The intersections of these two curves correspond
to steady states of the model. The number of steady states is con-
trolled by the value of E2 level. When E2 = 1, there is one stable
steady state corresponding to low GFR and low EPI (GFR/EPI).
When E2 is reduced below 0.65, there are three steady states,
two of which are stable and a third which is unstable. The stable
steady states have GFR and EPI levels that are either both low
(GFR/EPI) or both high (GFR+/EPI+). Fig. 1C illustrates how the
steady states of the system change with E2. The system has three
steady states in the range of 0 < E2 < 0.65 and only one stable stea-
dy state when E2 > 0.65. However, E2 is not the only parameter
that inﬂuences the system’s bistability. GFRover, which represents
the inﬂuence of additional GFR genes transfected into MCF7 cells,
can also be used as a bifurcation parameter. Fig. 2A shows that
when E2 is held constant at E2 = 1 the system is bistable only when
3.2 < GFRover < 12.8. We will show how this bistable survival-
signaling switch can explain the results of several important exper-
iments that are difﬁcult to understand without a model.
3.2. Three distribution patterns of GFR
Liu et al. transfected HER2 cDNA into MCF7 cells and created
multiple stable sub-clones, which were further screened for
HER2 protein expression levels using ﬂow cytometry. Interestingly,
three HER2 distribution patterns were observed in the sub-clones
they selected [43]: (1) a single peak of cells with elevated HER2
protein (MB4 in Fig. 2B), (2) a single peak of cells with low HER2
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Fig. 1. A model of the crosstalk between ER and GFR pathways exhibits bistable switching properties. (A) Inﬂuence diagram of the model. E2, estrogen level; ERT, total ERa
level; E2ER, estrogen-dependent E2:ER complex; ERP, phosphorylated ER; GFR, growth factor receptor; EPI, epigenetic components in GFR pathway; GFRover, number of extra
GFR gene copies. (B) Nullclines of the system at different E2 levels. s, stable steady state; u, unstable steady state. (C) Bifurcation diagram of GFR, with E2 as the bifurcation
parameter. The curves trace the steady state level of GFR as a function of E2 level. For a given value of E2, a cell may express a low or high value of GFR (upper and lower solid
lines; the middle dashed line indicates a branch of unstable steady states).
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Fig. 2. Three distribution patterns of GFR are exhibited in GFR-transfected MCF7. (A) Signal–response curve for GFR as a function of GFRover. The steady-state value of GFR is
plotted as a function of GFRover (from 0 to 14). For intermediate values of GFRover, a cell may express either a low or high level of GFR (upper and lower solid lines; the middle
dashed line indicates a branch of unstable steady states). (B) Different HER2 distribution patterns in HER2-overexpressed MCF7 sub-clones. Sub-clones MB5, MB7 and MB4
represent three typical distribution patterns of HER2 observed in experiment. Experimental data are adapted from [43]. (C) Distribution of GFR in 500 cells that are
stochastically simulated at different values of GFRover (2, 8, and 14) for four months by starting from random initial conditions. GFR level = 10GFR in these histograms.
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bimodal (two-peaked) distribution of HER2 (MB7 in Fig. 2B).
Southern blotting was used to conﬁrm that, within a sub-clone,
all cells had the same number of integrated HER2 copies; hence,
the bimodal distribution did not result from varying genetic condi-
tions. Similar results in MCF7 cells transfected with EGFR have
been reported [44], but a satisfactory explanation for these obser-
vations is lacking.
The major difference between these sub-clones could be that
during transfection different numbers of HER2 or EGFR genes were
integrated into the individual cells that formed the sub-clones. In
our model, we use GFRover to denote the amount of transfectedGFR and have shown that the system is bistable only when GFRover
is within a speciﬁc range (Fig. 2A). When very few GFR gene copies
are integrated into the cell (e.g., GFRover = 2), the system has only
one stable steady state at low GFR expression, while integration of
a high number of copies (e.g., GFRover = 14) results in only one
stable steady state at high GFR expression. However, integration
of an intermediate number of copies (e.g., GFRover = 8) creates a
system with two stable steady states (either high or low GFR
expression). To model distribution patterns of GFR in a population
of cells, we performed 500 stochastic simulations (see Fig. 2C),
starting from random initial conditions, of four month duration
for each of three different cases (GFRover = 2, 8 and 14). The results
3330 C. Chen et al. / FEBS Letters 587 (2013) 3327–3334of these simulations clearly replicate the experimental observa-
tions. When GFRover = 2, there is only one peak of cells at a low
GFR level, corresponding to MB5 in Fig. 2B. When GFRover = 14,
there is only one peak of cells at a high GFR level, corresponding
to MB4 in Fig. 2B. And when GFRover = 8, two peaks of cells (bimo-
dal distribution) coexist, corresponding to MB7 in Fig. 2B. (We note
that the number of GFR gene copies actually transfected in the
experiments is unknown and so the values used here for GFRover
are arbitrary and can be rescaled if copy number data becomes
available.)
3.3. GFR bimodal distribution manipulated by E2
By using a sub-clone of MCF7 cells with a bimodal HER2 distri-
bution, Liu et al. further showed the sensitivity of HER2 expression
to culture conditions [43]. Growing the cells for 5 weeks in char-
coal-stripped fetal calf serum (CCS), which is depleted of E2, re-
sulted in a single peak of cells expressing high levels of HER2.
Similarly, Miller et al. reported that MCF7 cells transfected with
EGFR and cultured in CCS create a population consisting predomi-
nantly of cells with high EGFR levels [44]. However, wild type
MCF7 cells cultured in CCS for one year still show a population con-
sisting predominantly of cells with low EGFR levels [44].
Fig. 3 provides an explanation for these results. In normal MCF7
cells cultured with E2, the cells are on the lower branch (low GFR)
of Fig. 3A. When E2 is depleted, the cells will stay on this branch
unless stochastic variations are strong enough to occasionally push
a cell to the upper branch (high GFR, Fig. 3A). Note that there is a
signiﬁcant barrier separating the lower steady state from the
unstable steady state (middle branch). We simulated a population0 0.2 0.4 0.6 0.8 1
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Fig. 3. E2 withdrawal turns on GFR in GFR-transfected but not in normal MCF7 cells. (A, B
(GFRover = 0) and in GFR-transfected MCF7 cells (GFRover = 5). (C, D) Temporal evolu
(GFRover = 0) and for GFR-transfected MCF7 cells (GFRover = 5). In each case, 500 cells wof 500 MCF7 cells starting from low GFR in the E2-withdrawal con-
dition for ﬁve weeks. No cell jumped to the high-GFR state, and
there was no change in the GFR distribution pattern at the popula-
tion level (Fig. 3C). However, when GFR is transfected into MCF7
cells (GFRover = 5), the barrier at E2 = 0 disappears (Fig. 3B) and
the system only has one stable steady state at high GFR. Thus,
when starting from the low-GFR initial condition, all cells will
move to the high-GFR state. A simulation of 500 GFR-transfected
MCF7 cells for ﬁve weeks produced a change in the GFR distribu-
tion pattern similar to that reported by Liu et al. and Miller et al.
(Fig. 3D).
Experiments also show that the distribution pattern of GFR can
be reversibly controlled by E2 [43,44]. Growing the MB8 sub-clone
MCF7 cells (with bimodal HER2 distribution) in CCS for ﬁve weeks
resulted in a single peak at high HER2 (Fig. 4, top left). Continuing
to grow these cells in fetal calf serum (FCS), which contains E2,
gradually leads to the rise of a peak at low HER2 (Fig. 4, left panel)
[43]. Similar dynamics have also been reported in MCF7 cells with
EGFR overexpression [44]. Southern blots conﬁrmed that there was
no variation in transfected HER2 gene copy number during E2
manipulation; Northern blots showed that HER2 mRNA expression
is consistent with the protein level [43]. These data imply that ge-
netic mutations are not the cause of HER2 heterogeneity in these
MCF7 cells.
The bifurcation diagram in Fig. 3B provides an explanation for
these experimental results. Consider a population of GFR-
transfected MCF7 cells depleted of E2 (E2 = 0) and having high
GFR expression. If E2 is now provided to the cells (E2 = 1), they will
stay in the high-GFR state, but the barrier to transitioning to the
low-GFR state will be diminished. Given adequate time, stochastic0 0.2 0.4 0.6 0.8 1
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Fig. 4. GFR bimodal distribution is reversibly controlled by different E2 levels. Left
panel, experimental data adapted from [43]. The MB8 sub-clone of GFR-transfected
MCF7 cells showing a bimodal HER2 distribution was treated with a series of E2
conditions: CCS, without E2, for 5 weeks; FCS, with E2, for 5 weeks, 3 months and
4 months. Right panel, model simulations, showing the distribution of GFR level in
5000 GFR-transfected MCF7 cells (GFRover = 5) under the same conditions as the
experiments. GFR level = 10GFR in these histograms.
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branch. We simulated a population of 5000 cells under these con-
ditions, and the GFR distributions from the model compared well
with the experimental observations (Fig. 4, right panel). Note that
after E2 withdrawal, GFR-transfected MCF7 cells can switch on GFR
within weeks, but cells need months to turn off GFR after E2 addi-
tion. Our simulation also replicates this asymmetry in response
time (Figs. 3 and 4).
3.4. Role of ER overexpression
A recent study observed that ER overexpression in MCF7 cells
activates the ER-regulated genes pS2 and PR in the absence of E2
[42]. Prolonged culturing of these cells leads to proliferation in
E2-depleted conditions. However, this proliferation can still be
inhibited by faslodex (a pure ER antagonist), indicating the role
of E2-independent ER-P activation in maintaining cell prolifera-
tion. By contrast, long term culturing of wild type MCF7 cells in
the absence of E2 failed to cause resumed cell growth. More
interesting, the overexpression of ER by adenovirus gene transfec-
tion in their study was only transient, as evidenced by the com-
plete loss of co-transfected GFP protein after culturing the cells
for 12 weeks.
To understand these experimental results using our model, we
ﬁrst evaluated the role of ER overexpression. Fig. 5A shows bifurca-
tion diagrams of GFR level, with E2 as the bifurcation parameter, at
different ER levels (ERT = 1, 2 and 3). This ﬁgure shows that
increasing ER level decreases the barrier for cells to switch from
the GFR/ERP/EPI state to the GFR+/ERP+/EPI + state when E2
is deprived. Consequently, a transient increase of ER will also result
in a transient decrease of the barrier, opening a temporary window
to an increased probability of state transitions under noise. To
demonstrate this outcome, we stochastically simulated a popula-
tion of 10,000 cells and evaluated how transient ER overexpression
inﬂuences the frequency of transitions in E2-depleted MCF7 cells.
No transition was observed during one month of E2 depletion in
normal MCF7 cells (ERT = 1, Fig. 5B, left panel). However, inMCF7 cells with transiently over-expressed ER there were 80
transitions during a similar time window (Fig. 5B, right panel).
Cells that transition will have high levels of GFR, EPI, and ERP,
implying the capability of E2-independent cell growth. The num-
ber of transitions is inﬂuenced by the strength of the ERT pulse,
which was simulated with the following equation:
ERT ¼ ER0 þ ERover  et
ln2
T1=2 ð1Þ
where ER0 = 1, ERover = 1.8, T1/2 = 0.25 month, t starts from the time
of ER overexpression.
To capture the experimental proliferation data in E2-depleted
conditions, we created a simple population growth model
(Fig. 6A) given by the equations:
dN1
dt
¼ kp1  N1  kt  N1 ð2Þ
dN2
dt
¼ kt  N1 þ kp2  N2 ð3Þ
In these equations, N1 denotes the number of low-GFR, E2-
dependent MCF7 cells and N2 denotes the number of high-GFR,
E2-independent MCF7 cells. The two cell types have different pro-
liferation rates (kp1, kp2), and there is a transition rate, kt, which de-
scribes how fast a low-GFR cell can switch to a high-GFR cell under
E2-depleted conditions. Notice that kt = 0 in normal MCF7 cells,
since no transition is observed in Fig. 5B. Furthermore, kt is not a
constant in MCF7 cells with transient ER overexpression. To deter-
mine the dynamics of kt we stochastically simulated a population
of 6  106 cells with transiently overexpressed ER. The percentage
of cells having transitions within independent time intervals is
plotted in Fig. 6B (black bars), and the histogram was ﬁt by a func-
tion of the form:
ktðtÞ ¼ 11þ eaðtbÞ 
1
1þ ecðtdÞ  h ð4Þ
where ﬁtting parameters a, b, c, d and h are all positive values. The
red curve in Fig. 6B is the result of the ﬁt and describes how kt varies
with time in MCF7 cells with the transient ER overexpression we
consider. Using a standard curve ﬁtting method (Matlab Version
7.9.0, Curve Fitting Toolbox), we determined the best ﬁtting param-
eter values to be a = 3.322  103, b = 6  103, c = 4.802  104,
d = 1.587  104 and h = 7.029  108.
Choosing the parameters ERover = 1.8, kp1 = 3  105, and
kp2 = 2  105, our simulation results for total cell number
(N1 + N2) in Fig. 6 C,D match the experimental results (red dia-
monds and triangles) for both the normal and ER-overexpressed
cells. Thus, by combining models at two different scales (molecular
and population), we provide a plausible explanation for how tran-
sient ER overexpression can promote E2-independent growth in
MCF7 breast cancer cells.4. Discussion
Breast cancer is the most common invasive cancer in women.
Endocrine therapy, as the most successful targeted cancer therapy,
has been very effective in reducing breast cancer mortality.
However, resistance often develops and the recurrence rate of
breast cancer after targeted therapies remains unacceptably high.
The molecular mechanisms of acquired endocrine resistance have
been intensively studied both in vivo and in breast cancer cell lines,
such as ER+ MCF7 cells. Many genes have been postulated as key
players in acquired endocrine resistance [5,20,22,39], but despite
knowledge of their roles in cell survival and growth, little is known
about how the ‘escape’ paths are mechanistically activated,
dynamically regulated, and epigenetically maintained during the
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stochastic simulations of 10000 cells (20 cells are plotted for illustration). Right panel, 80 transitions are observed within a short time window during transient ER
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Red line, trace of a deterministic simulation; blue lines, traces of 20 stochastic simulations; the horizontal dotted line shows the threshold we set to score transitions
(EPI = 0.5).
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Fig. 6. A population growth model shows the effects of transient ER overexpression. (A) Schematic representation of the population growth model. kp1, kp2 = (speciﬁc birth
rate – speciﬁc death rate) for cell populations N1 and N2, respectively. kt = rate at which low-GFR cells switch to high-GFR cells. (B) Transition probability of MCF7 cells that
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(1000 min); Red line, ﬁtted curve showing how kt varies with time in ER-overexpressed MCF7 cells. (C) Experimental data (red diamonds) and simulation results (grey line)
for the dynamics of total cell number in normal MCF7 cells after E2 depletion. (D) Experimental data (red triangles) and simulation results (grey line) for the dynamics of total
cell number in transient ER-overexpressed MCF7 cells after E2 depletion. The pulse of ER overexpression is simulated by Eq. (1). Experimental data are adapted from [42].
3332 C. Chen et al. / FEBS Letters 587 (2013) 3327–3334development of endocrine resistance. Understanding the molecu-
lar mechanisms used by breast cancer cells to acquire resistance
to endocrine treatment is critical for designing new therapies for
breast cancer.Emergence of resistance is closely associated with cellular het-
erogeneity. It has been widely recognized that breast cancer cells,
including the well-studied MCF7 cells, are inherently heteroge-
neous. Distinct cell phenotypes in the same MCF7 cell population
C. Chen et al. / FEBS Letters 587 (2013) 3327–3334 3333can be observed. Upon treatment, individual MCF7 cells can have
diverse responses: while some cells die through apoptosis, others
remain alive [23]. MCF7 cells also exhibit heterogeneous expres-
sion of a few key proteins. For example, although the MCF7 cell line
is generally classiﬁed as ER+, a minority of these cells express low
levels of ER [46]. The bimodal experimental data considered in the
present work also supports the heterogeneity of cancer cells
[43,44].
What is the source of this heterogeneity? A population com-
prised of cancer cells with distinct phenotypes is usually attributed
to mutations resulting from the genomic instability of cancer cells.
However, this emphasis on genetic causes for heterogeneity has
been challenged, as summarized by Huang et al. [47]. Recent stud-
ies indicate that viability within a population of cancer cells can
also result from noisy gene expression and the fact that gene net-
works have multiple stable states, providing a non-genetic source
of heterogeneity [47]. The presence of cancer stem cells (CSCs) in
breast cancer strongly supports a non-genetic basis for tumor het-
erogeneity. There should be no genetic difference between CSCs
and differentiated ‘bulk’ cells unless they acquire new mutations.
CSCs, unlike bulk cells, are usually ER and dependent on the
GFR pathway to survive [48,49]. For example, evidence shows that
NFjB inhibitors can preferentially inhibit CSCs in MCF7 cells, but
not MCF7 bulk cells [50]. Moreover, CSCs have the potential to de-
velop into bulk cells, and vice versa. These reversible transitions
between stem cells and bulk cells are implicated in the well-
documented cellular mesenchymal–epithelial transition and epi-
thelial–mesenchymal transition. During either of these transitions,
cells are reported to have an increased or decreased ‘stemness’
associated with changes in expression of speciﬁc stem cell surface
markers [37].
In this work, a mathematical model based on a bistable switch
with an epigenetic component successfully explains ﬁve intriguing
experimental observations in MCF7 cells [42–44] (Figs. S1–S4). (1)
The bifurcation analysis in Fig. 2A shows that GFR-transfected
MCF-7 cells have three distinct possibilities for GFR expression
(low, both low and high, and high) depending on the number of
GFR copies that were transfected, explaining why different exper-
imental subclones exhibited these three different GFR proﬁles. (2)
For a subclone with a bimodal GFR expression, the model analysis
in Fig. 3B shows that E2 deprivation will force the cells into a high
GFR state, as the low GFR state disappears, and re-adding E2 will
return the cells to the bimodal state, in accord with experiment,
Fig. 4. (3) Fig. 3B also shows why the transition of a bimodal sub-
clone to a high GFR state upon E2 deprivation is fast, as there is
only one stable state and no barrier to cross to get there, while
reversing the transition by re-adding E2 is slow, as cells must tran-
sition across a barrier to regain the low GFR state. (4) For non-
transfected MCF-7 cells, the model analysis in Fig. 3A shows that
E2 deprivation will not result in a high GFR state, since there is a
large barrier preventing state switching, even though such depri-
vation does result in a high GFR state for the bimodal subclones,
Fig. 3B, as they have no barrier to cross. (5) The analysis in Fig. 5
shows that transient ER overexpression lowers the barrier to the
high GFR state during a small time window and allows a few
E2-deprived MCF-7 cells to cross the barrier. This explains why a
population of E2 deprived MCF-7 cells will die out, but a similar
population with a transient ER overexpression will eventually
regrow, Fig. 6.
It should be emphasized that the model we present here, be-
cause it is an abstract and simpliﬁed version of reality, has some
limitations. While a bistable switch is not unexpected, due to the
presence of positive feedback loops in the ER–GFR crosstalk net-
work, further experiments are required to conﬁrm the exact mech-
anism. In particular, we emphasize epigenetic regulation of GFR
promoters (EPI) in our current model, creating an epigenetic switchby assuming that EPI controls and is being controlled by GFR. The
reality could be more complicated, since cell differentiation and
de-differentiation processes are closely linked with both ER and
GFR pathways. MicroRNAs, epigenetic regulation, and inter-
cellular communications are implicated in differentiation/de-
differentiation processes [1,37,51]; however, much is unknown at
present. Moreover, cell-signaling networks may have as many
steady states as there are physiological states, each steady state
being represented in a subpopulation of cells within a cell culture
or tissue. The low-GFR, E2-dependent and the high-GFR,
E2-independent states are just two examples of many states that
are possible.
Notwithstanding these limitations, the model of a survival-sig-
naling switch presented here helps to understand certain dynamic
behaviors of breast cancer cells that are difﬁcult to comprehend by
intuitive reasoning alone. Reﬁning this model by obtaining data
from primary breast cancers, as opposed to cell lines, will increase
its clinical relevance and could aid in the search for new strategies
to overcome breast cancer resistance.
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